Myelin basic protein-like material in the urine of multiple sclerosis patients: relationships to clinical and neuroimaging changes

Abstract

Urinary myelin basic protein-like material (MBPLM) represents material which is cross-reactive with a cryptic epitope in peptide 84-89 of human myelin basic protein. While normally present at moderate levels in the adult, these levels rise higher in patients who have secondary progressive multiple sclerosis (MS). The increase in urine MBPLM correlates with the burden of disease detected by T2-weighted cranial magnetic resonance imaging. There is no correlation between urinary MBPLM and acute disease activity in relapsing-remitting MS. The first major need for improving the clinical utility of measurements of MBPLM in urine in MS patients is to delineate its exact chemical features so that assays may be improved and a potential biological role of the MBPLM better understood. The second major task is to apply the group data accumulated and apply them to individual patients. This could prove to be means to individually direct treatment and determine its effectiveness.

Keywords

multiple sclerosis urine myelin basic protein magnetic resonance imaging radioimmunoassay

Get full access to this article

View all access options for this article.

References

Lublin FD , Reingold SC. (1996) Defining the clinical course of multiple sclerosis: Results of an international survey . Neurology 46: 907-911 .

The IFNB Multiple Sclerosis Study Group . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 43: 655-661 .

Paty DW , Li DKB , UBC MS/MRI Study Group , IFNB Multiple Sclerosis Study Group . (1993) Interferon beta- 1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 43: 662-667 .

Jacobs LD et al. (1996) Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis . Ann Neurol 39: 285-294 .

Johnson KP et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial . Neurology 45: 1268-1276 .

Noseworthy JH , O'Brien PC , Mayo Clinic-Canadian Cooperative MS Study Group . (1997) The Mayo Clinic-Canadian Cooperative study of sulfasalazine (Salazopyrin EN) in active multiple sclerosis: preliminary report . Neurology 48: A340-A340 .

Weiner HL et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis . Science 259: 1321-1324 .

Andersen O et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis . Neurology 47: 895-900 .

Karussis DM et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation . Neurology 47: 341-346 .

10.

Whitaker JN , McFarland HF , Rudge P , Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: A critical analysis . Multiple Sclerosis 1: 37-47 .

11.

Bedell BJ , Narayana PA , Wolinsky JS. (1997) A dual approach for minimizing false lesion classifications on magnetic resonance images . MRM 37: 94-102 .

12.

Rudick R et al. (1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 42: 379-382 .

13.

Whitaker JN , Snyder DS. (1982) Myelin components in the cerebrospinal fluid in diseases affecting central nervous system myelin . Clin Immunol Allergy 2: 469-482 .

14.

Whitaker JN. (1998) Myelin basic protein in cerebrospinal fluid and other body fluids . Mult Scl 4: 16-21 .

15.

Cuzner ML , Norton WT. (1996) Biochemistry of demyelination . Brain Pathol 6: 231-242 .

16.

Morell P , Quarles RH , Norton WT. (1989) Formation, structure and biochemistry of myelin. In: Siegel G , Agranoff B , Albers RW , Molinoff P , (eds). Basic neurochemistry Raven Press: New York 109-136.

17.

Roach A et al. (1983) Characterization of cloned cDNA representing rat myelin basic protein: absence of expression in brain in shiverer mutant mice . Cell 42: 799-806 .

18.

Campagnoni AT. (1988) Molecular biology of myelin proteins from the central nervous system . J Neurochem 51: 1-14 .

19.

Kamholz J , deFerra F , Puckett C , Lazzarini RA. (1986) Identification of three forms of human myelin basic protein by cDNA cloning . Proc Natl Acad Sci USA 83: 4962-4966 .

20.

Moscarello MA. (1990) Myelin basic protein: A dynamically changing structure. In: Hashim GA , Moscarello M , (eds.) Dynamic Interactions of Myelin Proteins John Wiley: New York 25-48.

21.

Hashim GA , Eylar EH. (1969) The structure of the terminal regions of the encephalitogenic basic protein from bovine myelin . Arch Biochem Biophys 135: 324-333 .

22.

Ramwani JJ , Epand RM , Moscarello MA. (1989) Secondary structure of charge isomers of myelin basic protein before and after phosphorylation . Biochemistry 28: 6538-6543 .

23.

Chou FC-H , Chou C-HJ , Shapira R , Kibler RF. (1976) Basis of microheterogeneity of myelin basic protein . J Biol Chem 251: 2671-2679 .

24.

Deibler GE , Martenson RE. (1973) Chromatographic fractionation of myelin basic protein. Partial characterization and methylarginine contents of multiple forms . J Biol Chem 248: 2392-2396 .

25.

Deibler GE et al. (1975) The contribution of phosphor-ylation and loss of COOH-terminal arginine to the microheterogeneity of myelin basic protein . J Biol Chem 250: 7931-7938 .

26.

Baldwin GS , Carnegie PM. (1971) Isolation and partial characterization of methylated arginines from the encephalitogenic basic protein of myelin . Biochem J 123: 69-74 .

27.

Wood DD , Moscarello MA. (1989) The isolation, characterization, and lipid-aggregating properties of a citrul-line containing myelin basic protein . J Biol Chem 264: 5121-5127 .

28.

Fannon AM , Moscarello MA. (1990) Myelin basic protein is affected by reduced synthesis of myelin proteolipid proteininthe jimpy mouse . Biochem J 268: 105-110 .

29.

Whitaker JN et al. (1992) An immunochemical comparison of human myelin basic protein and its modified, citrullinated form, C8 . J Neuroimmunol 36: 135-146 .

30.

Martin R et al. (1991) T-cell recognition of a citrulline-containing myelin basic protein . Neurology 41: 257-258 .

31.

Whitaker JN , Chou CHJ , Chou FCH , Kibler RF. (1979) Antigenic regions for the humoral response to myelin basic protein . Mol Immunol 16: 495-501 .

32.

Day ED , Potter NT. (1986) Monoclonal and polyclonal antibodies to myelin basic protein determinants . J Neuroimmunol 10: 289-312 .

33.

Fallis RJ , Raine CS , McFarlin DE. (1989) Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitopespecific T cell line . J Neuroimmunol 22: 93-105 .

34.

Sakai K et al. (1988) Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein . J Neuroimmunol 19: 21-32 .

35.

Offner H et al. (1989) T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats . J Exp Med 170: 355-367 .

36.

Warren KG , Catz I , Steinman L. (1995) Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B-cell epitope and a model of its features . Proc Natl Acad Sci USA 92: 11061-11065 .

37.

Ota K et al. (1990) T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis . Nature 346: 183-187 .

38.

Bashir RM , Whitaker JN. (1980) Molecular features of immunoreactive myelin basic protein in cerebrospinal fluid of persons with multiple sclerosis . Ann Neurol 7: 50-57 .

39.

Gibson BW , Gilliom RD , Whitaker JN , Biemann K. (1984) Amino acid sequence of human myelin basic protein peptide 45-89 as determined by mass spectrometry . JBiol Chem 259: 5028-5031 .

40.

Whitaker JN et al. (1995) Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis . Ann Neurol 38: 625-632 .

41.

Stoner GL. (1984) Predicted folding of b-structure in myelin basic protein . J Neurochem 43: 433-447 .

42.

Zhou SR , Whitaker JN. (1990) An idiotype shared by monoclonal antibodies to different peptides of human myelin basic protein . J Immunol 145: 2554-2560 .

43.

Zhou S-R et al. (1998) A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis . Neurology 50: 411-417 .

44.

Whitaker JN , Bashir RM , Chou C-H , Kibler RF. (1980) Antigenic features of myelin basic protein-like material in cerebrospinal fluid . J Immunol 124: 1148-1153 .

45.

Percy AK , Goodwin J , Whitaker JN. (1996) Myelin basic protein-like material in urine: a developmental profile . Ann Neurol 40: 297-297 .

46.

Whitaker JN et al. (1994) Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis . Ann Neurol 35: 577-585 .

47.

Whitaker JN , Chou CHJ , Chou FCH , Kibler RF. (1977) Molecular internalization of a region of myelin basic protein . J Exp Med 146: 317-331 .

48.

Whitaker JN. (1984) Indicators of disease activity in multiple sclerosis: Studies of myelin basic protein-like materials . Ann NY Acad Sci 436: 140-150 .

49.

Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

50.

Giovannoni G , Green A , Keir G , Thompson EJ. (1996) Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis - Letter to Editor . Ann Neurol 40: 128-129 .

51.

Whitaker JN. (1987) The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis . Ann Neurol 22: 648-655 .